ClinicalTrials.gg

Program

zetrukibart

In Sanofi's pipeline, IL1R3 mAb. Its studies are mostly in Hidradenitis Suppurativa · Bronchiectasis, led by Sanofi.

Furthest: phase 2, since Nov 4, 20252 company-led studies, 1 open or runningNext primary completion: Sep 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi21 open or runningphase 2since Nov 4, 2025Nov 4, 2025Sep 22, 2027phase 2 · NCT07225569
  • Named in Sanofi’s own pipeline as SAR445399, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2025First study: phase 2 study in Hidradenitis SuppurativaFirst studyNCT07225569 · 144 planned · United States, Argentina, Australia and more
  2. Apr 17, 2026Phase 2 study in BronchiectasisNCT07547436 · 70 enrolled · United States

Ahead

  1. Sep 22, 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07225569

TargetBeta

“IL1R3 mAb”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07547436Bronchiectasis · United States2SuspendedOct 29, 202770
NCT07225569Hidradenitis Suppurativa · United States, Argentina, Australia and more2RecruitingSep 22, 2027144

How it is read

Names in the registry

  • “SAR445399”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.